{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:21:24Z","timestamp":1777861284454,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["170707"],"award-info":[{"award-number":["170707"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000028","name":"CIHR ICRH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ijbiomac.2021.07.013","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T11:30:32Z","timestamp":1625484632000},"page":"490-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2"],"prefix":"10.1016","volume":"186","author":[{"given":"Pravas Kumar","family":"Baral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.G.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0010","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.arcmed.2020.04.021","article-title":"COVID-19: developing from an outbreak to a pandemic","volume":"51","author":"Hanaei","year":"2020","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0020","first-page":"81","article-title":"The Battle against COVID-19: where do we stand Now?","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iran J Med Sci."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0030","first-page":"231","article-title":"The rise and fall in therapeutic candidates for COVID-19","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iran J Med Sci."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","article-title":"Dysregulation of type I interferon responses in COVID-19","volume":"20","author":"Acharya","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0040","article-title":"Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells","author":"Muus","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0045","article-title":"SARS-CoV-2 uses clathrin-mediated endocytosis to gain access into cells","author":"Bayati","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J. Pharmaceut. Anal."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection\u2013a review of immune changes in patients with viral pneumonia","volume":"9","author":"Lin","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0070","series-title":"A Current Emerging Respiratory Infection: Epidemiological and Clinical Characteristics, Diagnosis and Treatments of COVID-19, Diagnosis and Treatments of COVID-19","author":"Yuan","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0075","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/22221751.2020.1736644","article-title":"A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses","volume":"9","author":"Fung","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0080","doi-asserted-by":"crossref","DOI":"10.3949\/ccjm.88a.ccc073","article-title":"Baricitinib and dexamethasone for hospitalized patients with COVID-19","author":"Calabrese","year":"2021","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0085","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(20)30691-7","article-title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","volume":"395","author":"Ritchie","year":"2020","journal-title":"Lancet"},{"issue":"157\u2013176","key":"10.1016\/j.ijbiomac.2021.07.013_bb0090","first-page":"ix","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: the role of cytokines in COVID-19 disease","volume":"54","author":"Costela-Ruiz","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","article-title":"Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts","volume":"108","author":"Wang","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0110","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ajem.2020.04.035","article-title":"Pharmacotherapy in COVID-19; a narrative review for emergency providers","volume":"38","author":"Mehta","year":"2020","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06158","article-title":"Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19","volume":"7","author":"Patel","year":"2021","journal-title":"Heliyon."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0120","first-page":"43","article-title":"Vaccines for COVID-19: the current state of play","volume":"35","author":"Koirala","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020153","article-title":"Progress and prospects on vaccine development against sars-cov-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0130","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0135","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0140","unstructured":"Sinopharm Sinovac COVID-19 vaccine data show efficacy: WHO https:\/\/www.reuters.com\/article\/us-health-coronavirus-who-china-vaccines-idUSKBN2BN1K8."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0145","unstructured":"AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/azd1222hlr.html."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.18433\/jpps31002","article-title":"Current drugs with potential for treatment of covid-19: a literature review","volume":"23","author":"Rabby","year":"2020","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0155","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1056\/NEJMcibr2032888","article-title":"Emergence of a highly fit SARS-CoV-2 variant","volume":"383","author":"Baric","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0160","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo","volume":"370","author":"Hou","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/d41586-020-02944-8","article-title":"COVID-19 vaccines: time to talk about the uncertainties","volume":"586","author":"Subbarao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0170","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0175","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jmv.25733","article-title":"Clinical trial analysis of 2019-nCoV therapy registered in China","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"4","author":"Arabi","year":"2015","journal-title":"Springerplus"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0185","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinf.2013.03.015","article-title":"Cross-reactive antibodies in convalescent SARS patients\u2019 sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0190","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/vox.12926","article-title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?","volume":"115","author":"Tiberghien","year":"2020","journal-title":"Vox Sang."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0195","first-page":"1","article-title":"Convalescent plasma transfusion for the treatment of COVID-19: systematic review","volume":"2020","author":"Rajendran","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0200","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102790","article-title":"Treatment for emerging viruses: convalescent plasma and COVID-19","volume":"59","author":"Brown","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0210","doi-asserted-by":"crossref","DOI":"10.1111\/trf.16392","article-title":"Convalescent plasma treatment of critically ill intensive care COVID-19 patients","author":"Lindemann","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0215","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019","volume":"222","author":"Zeng","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0220","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104358","article-title":"Challenges of convalescent plasma therapy on COVID-19","volume":"127","author":"Zhao","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0230","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaci.2020.04.043","article-title":"Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients\u2014a perspective","volume":"146","author":"Hammarstr\u00f6m","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0235","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/bjh.16981","article-title":"Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery","volume":"190","author":"Clark","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0240","volume":"59","author":"\u00c7inar","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0245","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0250","first-page":"10","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19)","volume":"38","author":"Shanmugaraj","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0255","article-title":"Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2","author":"Park","year":"2020","journal-title":"ParkbioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0265","series-title":"New Microbes and New Infections","article-title":"A short review on antibody therapy for COVID-19","volume":"35","author":"Venkat Kumar","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41426-018-0031-3","article-title":"Human transbodies that interfere with the functions of ebola virus VP35 protein in genome replication and transcription and innate immune antagonism","volume":"7","author":"Seesuay","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0275","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"Trial investigators, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0280","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"2020","key":"10.1016\/j.ijbiomac.2021.07.013_bb0285","first-page":"382","article-title":"Novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2019","journal-title":"Emerging Microbes and Infections."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0290","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0295","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s11427-017-9189-3","article-title":"Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses","volume":"60","author":"Zeng","year":"2017","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0300","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0305","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/21645515.2020.1735227","article-title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics","volume":"16","author":"Dhama","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0310","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0315","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0320","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0325","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0330","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0340","article-title":"Potent human neutralizing antibodies elicited by SARS-CoV-2 infection","author":"Ju","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0345","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41423-020-0385-z","article-title":"Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0350","doi-asserted-by":"crossref","first-page":"34610","DOI":"10.1074\/jbc.M603275200","article-title":"Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R","volume":"281","author":"Hwang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0355","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0360","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1073\/pnas.0701000104","article-title":"Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies","volume":"104","author":"Zhu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050366","article-title":"Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing","volume":"7","author":"Elshabrawy","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0370","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm1080","article-title":"An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus","volume":"10","author":"Traggiai","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0375","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.virol.2006.09.029","article-title":"Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse\u00ae","volume":"361","author":"Coughlin","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0380","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2807\/1560-7917.ES.2020.25.28.2000291","article-title":"Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARSCoV-2","volume":"25","author":"Zheng","year":"2020","journal-title":"Eurosurveillance."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0385","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0390","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0395","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-016-0234-7","article-title":"Surface vimentin is critical for the cell entry of SARS-CoV","volume":"23","author":"Yu","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0400","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1462-5822.2005.00506.x","article-title":"How C-type lectins detect pathogens","volume":"7","author":"Cambi","year":"2005","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0405","doi-asserted-by":"crossref","first-page":"12090","DOI":"10.1128\/JVI.78.21.12090-12095.2004","article-title":"DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"Marzi","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0410","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/JVI.78.11.5642-5650.2004","article-title":"pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN","volume":"78","author":"Yang","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0415","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0420","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antib4010012","article-title":"Cell-free synthesis meets antibody production: a review","volume":"4","author":"Stech","year":"2015","journal-title":"Antibodies"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0425","article-title":"LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection","author":"Jones","year":"2020","journal-title":"BioRxiv."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0430","series-title":"Bamlanivimab Emergency Use Authorization letter dated November 9","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0435","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"BLAZE-1 investigators, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0440","first-page":"205","article-title":"COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19","volume":"3","author":"Yang","year":"2020","journal-title":"Antib. Ther."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0445","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0450","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0455","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41467-020-20602-5","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0460","unstructured":"Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform https:\/\/financialpost.com\/pmn\/press-releases-pmn\/business-wire-news-releases-pmn\/celltrion-develops-tailored-neutralising-antibody-cocktail-treatment-with-ct-p59-to-tackle-covid-19-variant-spread-using-its-antibody-development-platform."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0465","article-title":"Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail","author":"Dong","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0470","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0475","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0480","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0485","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2020.10.025","article-title":"Letter to the editor: neutralizing antibodies for the treatment of COVID-19","volume":"11","author":"Zhou","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0490","unstructured":"Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027 https:\/\/www.businesswire.com\/news\/home\/20201210006232\/en\/Tychan-to-Start-COVID-19-Phase-3-Clinical-Trial-For-Novel-Monoclonal-Antibody-TY027."},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0495","article-title":"The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2","author":"Cathcart","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0500","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/d41586-021-00650-7","article-title":"COVID antibody treatments show promise for preventing severe disease","volume":"591","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2021.07.013_bb0505","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.abc5881","article-title":"Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody","volume":"369","author":"Lv","year":"2020","journal-title":"Science"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813021014495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813021014495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:45:10Z","timestamp":1756788310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813021014495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":100,"alternative-id":["S0141813021014495"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.07.013","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}